UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 8-K/A

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)  October 22, 2009
                                                --------------------------------

                           Lightlake Therapeutics Inc.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

           Nevada                     333-139915                    N/A
- --------------------------------------------------------------------------------
(State or other jurisdiction         (Commission              (I.R.S. Employer
      of incorporation)              File Number)            Identification No.)

   225-230 Queens Quay W, Toronto, ON                                  M5J2Y7
- --------------------------------------------------------------------------------
(Address of principal executive offices)                             (Zip Code)

Registrant's telephone number, including area code  416-841-5414
                                                  ------------------------------

- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.01 Changes in Registrant's Certifying Accountant.

On August 17, 2009, Madrona Ventures Inc. (the "Company") now known as Lightlake
Therapeutics  Inc.  dismissed  its auditing  firm of Dale  Matheson  Carr-Hilton
Labonte  LLP.  On the same date,  August 17,  2009,  the  accounting  firm of PS
Stephenson  & Co.,  P.C.,  CPA was  engaged  as the  Company's  new  independent
auditing firm.  The decision to change  auditing firms was approved by the board
of directors of the Company.

Over the past two fiscal  years our  former  auditor's  report on our  financial
statements did not contain an adverse opinion,  a disclaimer of opinion,  or was
qualified or modified as to uncertainty,  audit scope or accounting  principles.
However,  our  former  auditor  has  raised  doubt in the  Company's  ability to
continue  as a going  concern.  In the two  most  recent  fiscal  years  and the
subsequent interim period through the date of dismissal the Company did not have
any  disagreements  with our former  auditing firm of Dale Matheson  Carr-Hilton
Labonte  LLP on any  matter of  accounting  principles  or  practice,  financial
statement disclosure, or auditing scope or procedure.

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lightlake Therapeutics Inc. --------------------------- (Registrant) Date 10/22/2009 ---------- /s/ Seijin Ki ------------- (Signature) Director and Secretary

                                                                      Exhibit 16


October 22, 2009


Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Re: Madrona Ventures Inc.

Ladies and Gentlemen:

We are the  former  independent  accountants  for  Madrona  Ventures  Inc.  (the
"Company"). We have been furnished with a copy of the Company's response to Item
4.01 of Form 8-K/A disclosing our dismissal as independent public accountants of
the  Company.  We  confirm  our  agreement  with  the  statements  made  in such
disclosure insofar as they relate to our firm. We are not in a position to agree
or disagree with the statements in such disclosure  regarding the appointment of
or consultations with new independent accountants by the Company.

Yours truly,

     "DMCL"

Dale Matheson Carr-Hilton LaBonte LLP
Chartered Accountants
Barry Hartley, CA